Skip to main content
Clinical Trials/NCT06894030
NCT06894030Not yet recruitingNot Applicable

Investigating the Longitudinal Efficacy of Cognitive Cueing and Video Intervention for Gait in People with Parkinson's Disease

Western University, Canada1 site in 1 country30 target enrollmentStarted: April 1, 2025Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Sponsor
Enrollment
30
Locations
1
Primary Endpoint
Mean Stride Length

Study Overview

Brief Summary

The goal of this clinical trial is to learn if cognitive cueing (eg., prompting individuals to think about taking big-long steps while walking), either as a stand- alone intervention or combined with a personalized gait training video, can improve gait (walking), mobility, and balance confidence for individuals with Parkinson's Disease. The main questions it aims to answer are:

  1. Does focusing on cognitive cues while walking improve gait, mobility, and balance confidence for individuals with Parkinson's Disease?
  2. Does incorporating a personalized gait training video alongside cognitive cueing lead to amplified improvements in gait, mobility, and balance confidence for individuals with Parkinson's Disease?

Researchers will compare how gait, mobility, balance confidence and quality of life change over time for participants when they practice walking with and without a cognitive cue alone, and when they practice with using a personalized gait training video.

The researchers are also interested in how participation in this trial will affect quality of life and conscious attention to gait.

Participants will

  • Complete walking trials on an instrumented mat that records data on their walking ability. These trials will be undertaken without a cognitive cue and while participants mentally rehearse a series of 3 cognitive cues (Take big long steps; Walk heel-toe; Stand up straight).
  • Be informed about which of the 3 cues best improved their walking and will receive a personalized gait training video for at home practice.
  • Complete online surveys that ask questions about their Parkinson's Disease, mobility, balance confidence quality of life and conscious attention to gait.
  • Visit the research facility 3 to 4 times during the study to have their gait (walking), mobility, balance confidence, quality of life and conscious attention to gait assessed and reassessed.
  • Practice both with and without their personalized video at home and keep a diary to record their practice sessions
  • Participate in a brief interview to discuss their experiences with the training and their perceptions of the effectiveness of cognitive cues and video-recorded feedback

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Crossover
Primary Purpose
Supportive Care
Masking
None

Eligibility Criteria

Ages
40 Years to 99 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Be diagnosed with Parkinson's Disease
  • •Be fluent in English
  • •Be able to walk independently and without a walking aid for at least 10 minutes
  • •Have no other cognitive or neurological impairments (e.g., brain tumours, recent concussion, stroke, brain injury)

Exclusion Criteria

  • •Deep Brain Stimulation (DBS) implant
  • •Standardized Mini Mental State Examination (SMMSE) score less than 24

Arms & Interventions

Video Start

Experimental

Intervention: Gait Training Video (Behavioral)

Video Start

Experimental

Intervention: Cognitive Cue (Behavioral)

Video Delay

Experimental

Intervention: Gait Training Video (Behavioral)

Video Delay

Experimental

Intervention: Cognitive Cue (Behavioral)

Outcomes

Primary Outcomes

Mean Stride Length

Time Frame: From baseline to the end of the study (~17 weeks after baseline) as follows: Week 0 (Baseline), Week 5 (Session 2); Week 9 (Session 3 Video Delay Group ONLY); Week 13 (Session 3 Video Start Group ONLY); Week 17 (Session 4 Video Delay Group ONLY)

Mean of stride length measured in centimeters (cm).

Variability iin Stride Length

Time Frame: From baseline to the end of the study (~17 weeks after baseline) as follows: Week 0 (Baseline), Week 5 (Session 2); Week 9 (Session 3 Video Delay Group ONLY); Week 13 (Session 3 Video Start Group ONLY); Week 17 (Session 4 Video Delay Group ONLY)

Coefficient of variation in stride length.

Mean of Stride Width

Time Frame: From baseline to the end of the study (~17 weeks after baseline) as follows: Week 0 (Baseline), Week 5 (Session 2); Week 9 (Session 3 Video Delay Group ONLY); Week 13 (Session 3 Video Start Group ONLY); Week 17 (Session 4 Video Delay Group ONLY)

Mean of stride width measured in centimeters (cm).

Variability in Stride Width

Time Frame: From baseline to the end of the study (~17 weeks after baseline) as follows: Week 0 (Baseline), Week 5 (Session 2); Week 9 (Session 3 Video Delay Group ONLY); Week 13 (Session 3 Video Start Group ONLY); Week 17 (Session 4 Video Delay Group ONLY)

Coefficient of variation in stride width.

Mean of Stride Velocity

Time Frame: From baseline to the end of the study (~17 weeks after baseline) as follows: Week 0 (Baseline), Week 5 (Session 2); Week 9 (Session 3 Video Delay Group ONLY); Week 13 (Session 3 Video Start Group ONLY); Week 17 (Session 4 Video Delay Group ONLY)

Mean of stride velocity measured in centimeters per second-squared (cm/s\^2).

Variability in Sride Velocity

Time Frame: From baseline to the end of the study (~17 weeks after baseline) as follows: Week 0 (Baseline), Week 5 (Session 2); Week 9 (Session 3 Video Delay Group ONLY); Week 13 (Session 3 Video Start Group ONLY); Week 17 (Session 4 Video Delay Group ONLY)

Coefficient of variation in stride velocity.

Mean of Double Support Time

Time Frame: From baseline to the end of the study (~17 weeks after baseline) as follows: Week 0 (Baseline), Week 5 (Session 2); Week 9 (Session 3 Video Delay Group ONLY); Week 13 (Session 3 Video Start Group ONLY); Week 17 (Session 4 Video Delay Group ONLY)

Mean double support time measured as a proportion (0-1). This is the proportion of a gait cycle spent with two feet on the ground.

Variability in Double Support Time

Time Frame: From baseline to the end of the study (~17 weeks after baseline) as follows: Week 0 (Baseline), Week 5 (Session 2); Week 9 (Session 3 Video Delay Group ONLY); Week 13 (Session 3 Video Start Group ONLY); Week 17 (Session 4 Video Delay Group ONLY)

Coefficient of variation in double support time

Timed Up and Go (TUG)

Time Frame: From baseline to the end of the study (~17 weeks after baseline) as follows: Week 0 (Baseline), Week 5 (Session 2); Week 9 (Session 3 Video Delay Group ONLY); Week 13 (Session 3 Video Start Group ONLY); Week 17 (Session 4 Video Delay Group ONLY)

Timed test of functional mobility where participants are recorded on the number of seconds it takes to stand up from a chair, walk 10ft, turn around, walk back 10ft, and sit back in the chair. Longer times suggest lower functional mobility.

Secondary Outcomes

  • Activities-specific Balance Confidence Scale (ABC)(From baseline to the end of the study (~17 weeks after baseline) as follows: Week 0 (Baseline), Week 5 (Session 2); Week 9 (Session 3 Video Delay Group ONLY); Week 13 (Session 3 Video Start Group ONLY); Week 17 (Session 4 Video Delay Group ONLY))
  • Gait-Specific Attentional Profile (G-SAP)(From baseline to the end of the study (~17 weeks after baseline) as follows: Week 0 (Baseline), Week 5 (Session 2); Week 9 (Session 3 Video Delay Group ONLY); Week 13 (Session 3 Video Start Group ONLY); Week 17 (Session 4 Video Delay Group ONLY))
  • Parkinson's Disease Quality of Life Questionnaire (PDQ-39)(From baseline to the end of the study (~17 weeks after baseline) as follows: Week 0 (Baseline), Week 5 (Session 2); Week 9 (Session 3 Video Delay Group ONLY); Week 13 (Session 3 Video Start Group ONLY); Week 17 (Session 4 Video Delay Group ONLY))
  • Standardized Mini Mental State Examination (SMMSE)(At baseline only)

Investigators

Sponsor
Western University, Canada
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Jeffrey Holmes

Associate Professor, School of Occupational Therapy

Western University, Canada

Study Sites (1)

Loading locations...

Similar Trials